Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd | Sector: Pharmaceuticals | ISIN: INE048B01027

₹ 290.00 (-1.83%) icon

24 Mar, 2023, 3:29:56 PM
Open
₹ 302.90
Prev. Close
₹ 295.40
Turnover(lac)
₹ 152.82
Day's High
₹ 314.90
Day's Low
₹ 288.00
52 Wk High
₹ 418.90
52 Wk Low
₹ 251.80
Book Value
₹ 55.02
Face Value
₹ 5.00
Mkt. Cap (Cr.)
₹ 759.74
P/E
33.31
EPS
8.78
Div. Yield
1.37

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 3/24/2023 3:29:56 PM

    ₹ 290 -5.40 -1.83
  • Open
  • ₹ 302.9
  • Prev. Close
  • ₹ 295.4
  • Turnover(Lac.)
  • ₹ 153
  • Day's High
  • ₹ 314.9
  • Day's Low
  • ₹ 288
  • 52 Week's High
  • ₹ 418.9
  • 52 Week's Low
  • ₹ 251.8
  • Book Value
  • ₹ 55.02
  • Face Value
  • ₹ 5
  • Mkt Cap (₹ Cr.)
  • 759.74
  • P/E
  • 33.31
  • EPS
  • 8.78
  • Divi. Yield
  • 1.37

Corporate Actions

31 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jan , 2023

12:00 AM

03 Nov , 2022

12:00 AM

03 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Aug , 2022

12:00 AM

AGM

Announcement date: 24 Aug , 2022

View Details

04 Aug , 2022

12:00 AM

04 Aug , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

16 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jun , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 May , 2022

12:00 AM

22 May , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

22 May , 2022

12:00 AM

04 May , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 May , 2022

12:00 AM

BookCloser

View Details

SHAREHOLDING SNAPSHOT
26 March , 2023 | 05:14 PM

PROMOTER - TOTAL68.71%

Indian: 68.71%

Foreign: 0%

NON-PROMOTER - TOTAL 31.29%

Institutions: 0.88%

Non-Institutions: 30.41%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Jagsonpal Pharmaceuticals Ltd News and Update

Image not found
  • 24 March, 2023 |
  • 4:03 PM

According to a BSE filing, the parties to the proposed transaction, for which a legally binding memorandum of understanding had previously been signed, had "executed a Share Purchase Agreement and finalized the transaction."

Article Image
Article Image
  • IIFL News Service |
  • 23 March, 2023 |
  • 4:02 PM
ad IconAd Image

FINANCIALS

No Data Available To Display Chart

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Jagsonpal Pharmaceuticals Ltd

  • Manish Gupta

  • Managing Director
  • Harsha Raghavan

  • Addtnl Non-Executive Director
  • Debasis Bikash Nandy

  • Independent Director
  • Radhika C Pereira

  • Addtnl Independent Director
  • Pallavi Dinodia

  • Addtnl Independent Director
  • Prithipal Singh Kochhar

  • Addtnl Non-Executive Director
  • Abhishek Joshi

  • Company Sec. & Compli. Officer

Summary

Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.The Companys R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. Its R&D activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.In the fiscal 2001, the companys sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from... Read More


Reports by Jagsonpal Pharmaceuticals Ltd


Reports by Jagsonpal Pharmaceuticals Ltd